Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) EBT (2020 - 2025)

Cytek Biosciences' EBT history spans 6 years, with the latest figure at -$4.0 million for Q4 2025.

  • For Q4 2025, EBT fell 139.05% year-over-year to -$4.0 million; the TTM value through Dec 2025 reached -$29.8 million, down 423.62%, while the annual FY2025 figure was -$29.8 million, 423.53% down from the prior year.
  • EBT reached -$4.0 million in Q4 2025 per CTKB's latest filing, up from -$7.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $10.3 million in Q4 2024 to a low of -$11.3 million in Q1 2025.
  • Average EBT over 5 years is -$2.2 million, with a median of -$2.4 million recorded in 2022.
  • Peak YoY movement for EBT: skyrocketed 1601.56% in 2021, then tumbled 5048.41% in 2025.
  • A 5-year view of EBT shows it stood at $444000.0 in 2021, then soared by 826.58% to $4.1 million in 2022, then decreased by 0.07% to $4.1 million in 2023, then soared by 151.11% to $10.3 million in 2024, then crashed by 139.05% to -$4.0 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's EBT are -$4.0 million (Q4 2025), -$7.8 million (Q3 2025), and -$6.8 million (Q2 2025).